Author
Vividion Therapeutics (United States)ORCID 0000-0001-8061-6136Unclaimed ORCID profile · follow to get notified of new preprints
4 papers
Recent·Most cited
F. Wieland Goetzke, Steffen M. Bernard, Cheng‐Wei Ju…·Benjamin F. Cravatt
The paper develops covalent ligands that specifically target a complexoform of TRMT112, revealing partner-specific functional effects through allosteric activation of METTL5.
Nilotpal Roy, Tine L Wyseure, I‐Chung Lo…·Matthew P. Patricelli
This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.
Joseph E. Klebba, Nilotpal Roy, Steffen M. Bernard…·Matthew P. Patricelli
The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.
Tyler M. McCullough, Vishakha Choudhary, David L. Akey…·Janet Lynn Smith
This study investigates how polyketide synthase thioesterase domains direct substrate nucleophiles for macrolactone formation by analyzing structural and functional properties of modified TEs.